Holen Sie sich die Stockscreener-App
0.785
8.83%
-0.076
Vorhandelsmarkt:
.81
0.025
+3.18%
Schlusskurs vom Vortag:
$0.861
Offen:
$0.8235
24-Stunden-Volumen:
951.75K
Relative Volume:
0.78
Marktkapitalisierung:
$73.01M
Einnahmen:
$34.48M
Nettoeinkommen (Verlust:
$-102.07M
KGV:
-0.5377
EPS:
-1.46
Netto-Cashflow:
$-104.90M
1W Leistung:
-20.60%
1M Leistung:
-26.64%
6M Leistung:
-56.15%
1J Leistung:
-83.23%
1-Tages-Spanne:
$0.7811
$0.8501
1-Wochen-Bereich:
$0.7155
$1.00
52-Wochen-Spanne:
$0.7155
$4.85
Caribou Biosciences Inc Stock (CRBU) Company Profile
Firmenname
Caribou Biosciences Inc
Sektor
Branche
Telefon
510-982-6030
Adresse
2929 7TH STREET, SUITE 105, BERKELEY
Vergleichen Sie CRBU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
0.785 | 73.01M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Eingeleitet | Evercore ISI | Outperform |
| 2023-07-11 | Eingeleitet | Truist | Buy |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-17 | Eingeleitet | BofA Securities | Buy |
| 2021-08-17 | Eingeleitet | Citigroup | Neutral |
| 2021-08-17 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Caribou Biosciences Inc Aktie (CRBU) Neueste Nachrichten
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - Markets Insider
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts - Defense World
Caribou Biosciences stock hits 52-week low at $0.95 By Investing.com - Investing.com Canada
Caribou Biosciences stock hits 52-week low at $0.95 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation - Markets Insider
Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out - Markets Insider
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture - Investing.com Canada
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture By Investing.com - Investing.com South Africa
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19 - Marketscreener.com
US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect - Markets Insider
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock By Investing.com - Investing.com Australia
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock - Investing.com India
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates - MSN
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in its Shares - Markets Insider
Caribou Biosciences stock hits 52-week low at $1 By Investing.com - Investing.com Australia
Caribou Biosciences stock hits 52-week low at $1 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
CRBU FY2029 EPS Reduced by Brookline Capital Management - Defense World
Caribou Biosciences Brass Face Investor's Clinical Trials Suit - Law360
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GuruFocus.com
Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation - Markets Insider
RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk - Marketscreener.com
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Caribou Biosciences reports Q4 EPS (39c), consensus (42c) - TipRanks
Caribou Biosciences shares rise on narrower-than-expected Q4 loss By Investing.com - Investing.com Australia
Caribou Biosciences shares rise on narrower-than-expected Q4 loss - Investing.com India
Caribou Biosciences, Inc. SEC 10-K Report - TradingView
Caribou Biosciences, Inc. Anticipates Clinical Data from CB-010 and CB-011 in H1 2025 Amidst Advancements in Hematologic Malignancies and Autoimmune Disease Therapies - Nasdaq
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - The Bakersfield Californian
Caribou Biosciences, Inc. Sued for Securities Law ViolationsI - GuruFocus.com
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Caribou Biosciences Leaders Overhyped Cancer Therapy, Suit Says - Bloomberg Law News
Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts - Defense World
Institutional investors may adopt severe steps after Caribou Biosciences, Inc.'s (NASDAQ:CRBU) latest 13% drop adds to a year losses - Simply Wall St
Caribou Biosciences stock hits 52-week low at $1.22 - Investing.com
Caribou Biosciences stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Finanzdaten der Caribou Biosciences Inc-Aktie (CRBU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):